<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579436</url>
  </required_header>
  <id_info>
    <org_study_id>74457</org_study_id>
    <secondary_id>P20RR021954</secondary_id>
    <nct_id>NCT00579436</nct_id>
  </id_info>
  <brief_title>Effects of Fish Oils on Inflammation and Insulin Resistance</brief_title>
  <official_title>Effects of Fish Oils on Inflammation and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Kern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether improvement in fat and muscle metabolism
      after the treatment with Omacor (fish oils) provides insight into the link between obesity,
      fat and muscle function leading to metabolic syndrome, which is a risk factor for heart
      disease and diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The development of type 2 diabetes (T2DM) represents a complex series of events, involving
      abnormalities in adipose tissue lipid distribution and insulin action. Along with an increase
      in adipose tissue mass is an increase in inflammation brought about by macrophages that
      infiltrate adipose tissue. These macrophages express inflammatory cytokines such as tumor
      necrosis factor (TNF) and Interleukin -6 (IL-6) which are correlated with insulin resistance
      and metabolic syndrome, and suggest that metabolic syndrome and diabetes are conditions
      characterized by a state of chronic, low-grade inflammation. Thiazolidinediones (TZDs)
      improve insulin sensitivity via activation of peroxisome proliferator-activated receptor
      (PPAR) , and there is much evidence that PPAR agonists also have anti-inflammatory
      properties.

      Fish oils are rich sources of Omega-3 fatty acids and there is a large literature on the
      potential benefits of fish oils on lowering serum triglycerides, cardiovascular protection,
      and immune modulation, and there is evidence that fish oils also activate PPAR . Hence, the
      focus of this study will be on subjects with insulin resistance and metabolic syndrome, but
      who do not yet have diabetes. We plan to treat insulin resistant subjects with fish oils and
      ask the following questions.

      Hypothesis 1. The treatment of insulin resistant subjects with fish oils will reduce adipose
      tissue inflammation.

      Aim 1. From blood samples drawn before and after treatment, we will measure levels of
      circulating inflammatory cytokines.

      Aim 2. Adipose tissue biopsies will be performed before and after fish oil treatment. From
      the adipose biopsies, we will quantitate cytokine expression, macrophage number, and we will
      look for evidence of macrophage apoptosis.

      Aim 3. We will determine whether fish oil treatment increases the adipose tissue secretion
      and serum level of the high molecular weight form of adiponectin.

      Hypothesis 2. The reduction in inflammatory markers occurs through an activation of PPAR by
      the fish oils.

      Aim 4. Adipose tissue and macrophages will be treated in vitro with fish oils in the presence
      and absence of a PPAR inhibitor. We will determine whether fish oils stimulate the secretion
      of the high molecular weight adiponectin isoform from adipose tissue and whether they induce
      apoptosis from macrophages, and whether this process is inhibited by the PPAR inhibitor.

      Hypothesis 3. Fish oils improve peripheral insulin sensitivity through a reduction in
      intramyocellular lipid, and an improvement in muscle insulin signal transduction.

      Aim 5. Before and after treatment with fish oils, insulin sensitivity will be measured, along
      with intramyocellular lipid and genes involved in insulin action and muscle lipid oxidation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 15, 2015</completion_date>
  <primary_completion_date type="Actual">March 27, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Adipocyte Size</measure>
    <time_frame>baseline</time_frame>
    <description>Prior to starting the fish oil regiment, participants will undergo an incisional abdominal biopsy to remove approximately 4g of adipose tissue to determine adipocyte size</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adipocyte Size After Fish Oil Treatment</measure>
    <time_frame>week 12</time_frame>
    <description>After completing the fish oil regiment, participant will undergo an incisional abdominal biopsy to remove approximately 4g of adipose tissue to determine individual adipocyte size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Insulin Resistance</measure>
    <time_frame>baseline</time_frame>
    <description>Insulin sensitivity (Si) was measured with a frequently sampled intravenous glucose tolerance test. Participants received a bolus of glucose at Time Zero, then a bolus of insulin 20 minutes later. Blood was collected through an IV catheter at multiple time points over the course of 4 hours. Glucose levels were plotted on a time course curve and analyzed using the MIDMOD algorithm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance After Fish Oil Regiment</measure>
    <time_frame>week 12</time_frame>
    <description>Insulin sensitivity (Si) was measured with a frequently sampled intravenous glucose tolerance test. Participants received a bolus of glucose at Time Zero, then a bolus of insulin 20 minutes later. Blood was collected through an IV catheter at multiple time points over the course of 4 hours. Glucose and Insulin levels will be plotted on a time course curve and analyzed using the MINMOD algorithm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Fish oil group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4g Lovaza (omega-3 fatty acid) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (4 non-active capsules daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 fatty acid</intervention_name>
    <description>4g of omega-3 fatty acid daily by mouth for 12 weeks.</description>
    <arm_group_label>Fish oil group</arm_group_label>
    <other_name>Lovaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>4 inert capsules daily by mouth for 12 weeks.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 27-45 kg/m2

          -  age 35-65 years

          -  abnormal carbohydrate metabolism

        Exclusion Criteria:

          -  triglycerides over 700 mg/dl

          -  renal disease

          -  liver disease

          -  congestive heart failure

          -  history of heart disease or stroke

          -  chronic aspirin or NSAID use (anti-coagulant)

          -  history of a bleeding disorder

          -  use of statins, fibrates, ACE inhibitors, angiotensin II receptor blockers and
             glucocorticoids

          -  diet heavy in omega-3 fatty acids (salmon, sardines, flaxseeds)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip A. Kern, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky Medical Cener</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40475</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Spencer M, Finlin BS, Unal R, Zhu B, Morris AJ, Shipp LR, Lee J, Walton RG, Adu A, Erfani R, Campbell M, McGehee RE Jr, Peterson CA, Kern PA. Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. Diabetes. 2013 May;62(5):1709-17. doi: 10.2337/db12-1042. Epub 2013 Jan 17.</citation>
    <PMID>23328126</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <results_first_submitted>February 13, 2018</results_first_submitted>
  <results_first_submitted_qc>April 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 16, 2018</results_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Philip Kern</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>obesity</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Non-diabetic subjects with either impaired glucose tolerance, impaired fasting glucose, or at least three features of metabolic syndrome were recruited at the University of Kentucky or the University of Arkansas. Exclusion criteria included history of coronary heart disease, inflammatory disease or chronic anti-inflammatory use</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fish Oil Group</title>
          <description>4g Lovaza (omega-3 fatty acid) daily.
omega-3 fatty acid: 4g of omega-3 fatty acid daily by mouth for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>placebo (4 non-active capsules daily)
placebo: 4 inert capsules daily by mouth for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fish Oil Group</title>
          <description>4g Lovaza (omega-3 fatty acid) daily.
omega-3 fatty acid: 4g of omega-3 fatty acid daily by mouth for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>placebo (4 non-active capsules daily)
placebo: 4 inert capsules daily by mouth for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="9.8"/>
                    <measurement group_id="B2" value="53.3" spread="8.3"/>
                    <measurement group_id="B3" value="50.8" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.8" spread="12.5"/>
                    <measurement group_id="B2" value="92.1" spread="16.9"/>
                    <measurement group_id="B3" value="96.8" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body fat</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="7.4"/>
                    <measurement group_id="B2" value="46.2" spread="10.1"/>
                    <measurement group_id="B3" value="44.9" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.4" spread="5.4"/>
                    <measurement group_id="B2" value="33.8" spread="4.3"/>
                    <measurement group_id="B3" value="33.4" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150" spread="57.92"/>
                    <measurement group_id="B2" value="163.0" spread="82.8"/>
                    <measurement group_id="B3" value="155.7" spread="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207.1" spread="41.6"/>
                    <measurement group_id="B2" value="204.7" spread="44.5"/>
                    <measurement group_id="B3" value="206" spread="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High density lipoprotein</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="15.21"/>
                    <measurement group_id="B2" value="47.7" spread="12.2"/>
                    <measurement group_id="B3" value="49.50" spread="13.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low density lipoprotein</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125.9" spread="36.8"/>
                    <measurement group_id="B2" value="122.4" spread="40.8"/>
                    <measurement group_id="B3" value="125.5" spread="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2 hour Glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.8" spread="43.3"/>
                    <measurement group_id="B2" value="157.8" spread="29.0"/>
                    <measurement group_id="B3" value="163.1" spread="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" spread=".3"/>
                    <measurement group_id="B2" value="5.6" spread="0.4"/>
                    <measurement group_id="B3" value="5.8" spread=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Adipocyte Size</title>
        <description>Prior to starting the fish oil regiment, participants will undergo an incisional abdominal biopsy to remove approximately 4g of adipose tissue to determine adipocyte size</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil Group</title>
            <description>4g Lovaza (omega-3 fatty acid) daily.
omega-3 fatty acid: 4g of omega-3 fatty acid daily by mouth for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>placebo (4 non-active capsules daily)
placebo: 4 inert capsules daily by mouth for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Adipocyte Size</title>
          <description>Prior to starting the fish oil regiment, participants will undergo an incisional abdominal biopsy to remove approximately 4g of adipose tissue to determine adipocyte size</description>
          <units>square micrometers</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4958" spread="249"/>
                    <measurement group_id="O2" value="4489" spread="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adipocyte Size After Fish Oil Treatment</title>
        <description>After completing the fish oil regiment, participant will undergo an incisional abdominal biopsy to remove approximately 4g of adipose tissue to determine individual adipocyte size</description>
        <time_frame>week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil Group</title>
            <description>4g Lovaza (omega-3 fatty acid) daily.
omega-3 fatty acid: 4g of omega-3 fatty acid daily by mouth for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>placebo (4 non-active capsules daily)
placebo: 4 inert capsules daily by mouth for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adipocyte Size After Fish Oil Treatment</title>
          <description>After completing the fish oil regiment, participant will undergo an incisional abdominal biopsy to remove approximately 4g of adipose tissue to determine individual adipocyte size</description>
          <units>square micrometers</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4869" spread="209"/>
                    <measurement group_id="O2" value="4051" spread="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Insulin Resistance</title>
        <description>Insulin sensitivity (Si) was measured with a frequently sampled intravenous glucose tolerance test. Participants received a bolus of glucose at Time Zero, then a bolus of insulin 20 minutes later. Blood was collected through an IV catheter at multiple time points over the course of 4 hours. Glucose levels were plotted on a time course curve and analyzed using the MIDMOD algorithm.</description>
        <time_frame>baseline</time_frame>
        <population>all participants were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil Group</title>
            <description>4g Lovaza (omega-3 fatty acid) daily.
omega-3 fatty acid: 4g of omega-3 fatty acid daily by mouth for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>placebo (4 non-active capsules daily)
placebo: 4 inert capsules daily by mouth for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Insulin Resistance</title>
          <description>Insulin sensitivity (Si) was measured with a frequently sampled intravenous glucose tolerance test. Participants received a bolus of glucose at Time Zero, then a bolus of insulin 20 minutes later. Blood was collected through an IV catheter at multiple time points over the course of 4 hours. Glucose levels were plotted on a time course curve and analyzed using the MIDMOD algorithm.</description>
          <population>all participants were analyzed</population>
          <units>[mU/L]^-1 x [min]^-1]</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread=".2"/>
                    <measurement group_id="O2" value="1.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Resistance After Fish Oil Regiment</title>
        <description>Insulin sensitivity (Si) was measured with a frequently sampled intravenous glucose tolerance test. Participants received a bolus of glucose at Time Zero, then a bolus of insulin 20 minutes later. Blood was collected through an IV catheter at multiple time points over the course of 4 hours. Glucose and Insulin levels will be plotted on a time course curve and analyzed using the MINMOD algorithm.</description>
        <time_frame>week 12</time_frame>
        <population>all participants measured</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil Group</title>
            <description>4g Lovaza (omega-3 fatty acid) daily.
omega-3 fatty acid: 4g of omega-3 fatty acid daily by mouth for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>placebo (4 non-active capsules daily)
placebo: 4 inert capsules daily by mouth for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Resistance After Fish Oil Regiment</title>
          <description>Insulin sensitivity (Si) was measured with a frequently sampled intravenous glucose tolerance test. Participants received a bolus of glucose at Time Zero, then a bolus of insulin 20 minutes later. Blood was collected through an IV catheter at multiple time points over the course of 4 hours. Glucose and Insulin levels will be plotted on a time course curve and analyzed using the MINMOD algorithm.</description>
          <population>all participants measured</population>
          <units>[mU/L]^-1 x [min]^-1]</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread=".3"/>
                    <measurement group_id="O2" value="1.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fish Oil Group</title>
          <description>4g Lovaza (omega-3 fatty acid) daily.
omega-3 fatty acid: 4g of omega-3 fatty acid daily by mouth for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>placebo (4 non-active capsules daily)
placebo: 4 inert capsules daily by mouth for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study not being powered to identify a difference between groups</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Phillip Kern</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>859 323 4933</phone>
      <email>pake2222@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

